Roivant Sciences Investor

Roivant Sciences is a biopharmaceutical company focused on completing the development of promising late-stage drug candidates. Roivant’s mission is to reduce the time and cost of developing new medicines for patients and to share those savings with the healthcare system. Roivant does this by building Vants - nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying the technology. In addition to its biopharmaceutical subsidiaries, Roivant also builds technology-focused Vants focused on improving the process of developing and commercializing medicines.

Invests into

Technology: Biopharma, Biotechnology, Health Care, Pharmaceutical, Product Research
Industry: Clinical Development, Preclinical Development
Headquarters: New York, New York, United States
Founded Date: 2014-05-01
Employees Number: 501-1000
Funding Status: IPO
Number Of Exits: 2
Acquisitions Number: 2
Investors Number: 15
Total Funding: 2093000000
Estimated Revenue: $10M to $50M
Last Funding Date: 2021-10-01
Last Funding Type: Post-IPO Equity

Visit Website
info@roivant.com
https://twitter.com/roivant
Register and Claim Ownership